Broadly Protective Strategies Against Influenza Viruses: Universal Vaccines and Therapeutics

Vogel, O. A.; Manicassamy, Balaji

doi:10.3389/fmicb.2020.00135

Cited by 40 publications

(45 citation statements)

References 126 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The recent COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ( 1 ) has demonstrated the fragility of our health systems in tackling emergency situations related to the spread of new infectious agents that require the rapid development of effective care strategies. Unfortunately, there are several potentially pandemic viruses, such as flaviviruses (e.g., West Nile virus [WNV], dengue virus, and Zika virus) ( 2 ), chikungunya virus ( 3 ), influenza viruses A [e.g., A(H1N1) and A(H5N1)] ( 4 ), Ebola virus (EBOV) ( 5 ), and respiratory betacoronaviruses (SARS-CoV and Middle East respiratory syndrome-CoV [MERS-CoV]), which could put us in situations very similar to the situation with the current pandemic and which require the development of specific intervention protocols.…”

Section: Introductionmentioning

confidence: 99%

Convalescent Plasma Therapy for COVID-19: State of the Art

Focosi¹,

et al. 2020

View full text Add to dashboard Cite

SUMMARY Convalescent plasma (CP) therapy has been used since the early 1900s to treat emerging infectious diseases; its efficacy was later associated with the evidence that polyclonal neutralizing antibodies can reduce the duration of viremia. Recent large outbreaks of viral diseases for which effective antivirals or vaccines are still lacking has renewed the interest in CP as a life-saving treatment. The ongoing COVID-19 pandemic has led to the scaling up of CP therapy to unprecedented levels. Compared with historical usage, pathogen reduction technologies have now added an extra layer of safety to the use of CP, and new manufacturing approaches are being explored. This review summarizes historical settings of application, with a focus on betacoronaviruses, and surveys current approaches for donor selection and CP collection, pooling technologies, pathogen inactivation systems, and banking of CP. We additionally list the ongoing registered clinical trials for CP throughout the world and discuss the trial results published thus far.

show abstract

Section: Introductionmentioning

confidence: 99%

Convalescent Plasma Therapy for COVID-19: State of the Art

Focosi¹,

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Anti-M2e antibodies, however, mediate the protection by their effector function only (Jegerlehner et al, 2004;El Bakkouri et al, 2011). Recently published data suggest that the development of universal anti-influenza vaccine may be achieved by combination of suitable vaccine candidates, such as conserved epitopes from IAV u n c o r r e c t e d 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 proteins (HA, NP, M), and novel vaccination platforms (Nachbagauer and Palese, 2020;Vogel and Manicassamy, 2020). Further research is required to find an answer and for better understanding of these processes.…”

Section: Resultsmentioning

confidence: 99%

Universal anti-influenza vaccines based on viral HA2 and M2e antigens

Kostolanský¹,

Tomčíková²,

Briestenská³

et al. 2020

View full text Add to dashboard Cite

Aquatic birds are the main reservoir of influenza A viruses (IAVs). These viruses can infect humans repeatedly and cause acute respiratory disease with potential of spread in the form of epidemics. In addition, avian influenza viruses that overcome the interspecies barrier and adapt to humans can cause a worldwide pandemic with severe consequences to human health. Therefore, scientists are focused on the development of a "universal" vaccine with a broad protective efficacy, i.e. against different subtypes of influenza A viruses and not only against the currently co-circulating human epidemic strains. Nowadays, several new vaccine design strategies have been described. Most of them utilize the conserved stem part of influenza surface glycoprotein hemagglutinin (HA) or the ectodomain of M2 (M2e) protein with proton-channel activity. A comparison of the effectivity of novel vaccines and their protective mechanisms against influenza infection is discussed in this review and should be considered for the construction of the most effective broadly protective vaccine with minimal side effects. This is the essential goal in influenza virus research today, especially when the infection with new human coronavirus SARS-CoV-2 can interfere with the course of influenza virus infection.

show abstract

“…These antibodies are the key for universal protection against influenza. Blood samples analysis collected from influenza virus-infected or immunized individuals confirmed that most bnAbs target HA (Vogel and Manicassamy, 2020). In its trimeric conformation, each HA monomer is composed of the globular head domain formed by HA1 subunits and a long stem or stalk domain formed by HA2 subunits responsible of the fusion between viral and endosomal membrane.…”

Section: Learning From Other Pandemic Virusesmentioning

confidence: 93%

Prepare for the Future: Dissecting the Spike to Seek Broadly Neutralizing Antibodies and Universal Vaccine for Pandemic Coronaviruses

Vangelista

Secchi

2020

Front. Mol. Biosci.

View full text Add to dashboard Cite

Learning from the lengthy fight against HIV-1, influenza, and Ebola virus infection, broadly neutralizing antibodies (bnAbs), directed at conserved regions of surface proteins crucial to virus entry (Env, hemagglutinin, and GP, respectively), are an essential resource for passive as well as active immunization. Rare in their emergence and antigen recognition mode, bnAbs are active toward a large set of different viral strains. Isolation, characterization and production of bnAbs lead to their possible use in passive immunotherapy and form the basis for an educated effort in the development of vaccines for universal coverage. SARS-CoV-2-specific antibodies targeting the spike receptor binding domain (RBD) may lead to antibody dependent enhancement (ADE) of infection, possibly hampering the field of vaccine development. This perspective points to the identification of conserved regions in the spike of SARS-CoV-2, SARS-CoV, and MERS-CoV through investigation, dissection and recombinant production of isolated moieties. These spike moieties should be capable of independent folding and allow the detection as well as the elicitation of bnAbs, thus setting the basis for an effective passive immunotherapy and the development of a universal vaccine against human epidemic coronaviruses (HCoVs). SARS, MERS and, most of all, COVID-19 demonstrate that humanity is the target of HCoV, preparedness for future hits is thus no longer an option.

show abstract

Broadly Protective Strategies Against Influenza Viruses: Universal Vaccines and Therapeutics

Cited by 40 publications

References 126 publications

Convalescent Plasma Therapy for COVID-19: State of the Art

Convalescent Plasma Therapy for COVID-19: State of the Art

Universal anti-influenza vaccines based on viral HA2 and M2e antigens

Prepare for the Future: Dissecting the Spike to Seek Broadly Neutralizing Antibodies and Universal Vaccine for Pandemic Coronaviruses

Contact Info

Product

Resources

About